os of patients with mcrpc with pten loss-of-function identified by genomic profiling
Published 3 years ago • 82 plays • Length 3:38Download video MP4
Download video MP3
Similar videos
-
3:42
ctdna level variation as an early predictor of survival in patients with mcrpc
-
3:18
pi3k/akt pathway aberrations in mcrpc
-
10:01
evaluating the prognostic value of psma pet/ct in mcrpc
-
1:35
will genomic profiling replace clinical and pathological risk factors in er breast cancer?
-
4:55
18f-fluciclovine pet in mcrpc treated with abiraterone acetate
-
10:21
clarify: phase 3 diagnostic trial of 64cu-sar-bispsma pet imaging in prostate cancer before surgery
-
31:27
phosr enables processing and functional analysis of phosphoproteomic data
-
18:06
18f-psma-1007 pet/ct - sponsored by mayo clinic
-
4:56
improving the prognosis for patients with mcrpc
-
18:33
your role in precision management of advanced prostate cancer: molecular testing and hrr-deficiency
-
3:25
molecular profiling of esophagogastric cancer patient-derived xenografts
-
1:35
psma-pet scanning and management of cn1 prostate cancer
-
4:42
psma-targeted imaging with 18f-dcfpyl-pet/ct in patients with prostate cancer
-
1:37
dr. corn on sequencing agents for patients with mcrpc
-
3:50
psma pet imaging in defining mpc and understanding long-term dynamics and treatment implications
-
1:29
emerging treatment options for patients with prostate cancer
-
3:13
18f-dcfpyl pet/ct imaging up-stages patients with prostate cancer
-
5:09
benefits of upfront staging with psma-pet in high-risk prostate cancer
-
6:03
prostate-specific membrane antigen activated prodrug and imaging agents
-
1:01
evaluating tumor-directed pet imaging of mcrpc bone metastases using zr-89-j591
-
6:13
ep. 7: current treatment and imaging options for nmcrpc
-
1:14
rationale of phase iii pcs5 trial of hypofractionated radiotherapy for prostate cancer